Ascendiant Capital Maintains Buy on Surgepays, Lowers Price Target to $3.5

Benzinga Newsdesk www.benzinga.com Negative 76.0%

Neg 76% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:SURG) with a Buy and lowers the price target from $5 to $3.5.